​Genus Oncology completes enrollment to Phase 1b dose escalation study of GO-203 for the treatment of relapsed/refractory AML.

​Targeting of MUC1-C suppresses MYC expression and attenuates malignant growth in KRAS mutant lung cancer.  Study published in “Cancer Research”.  These findings demonstrate that targeting MUC1-C is a novel approach for downregulating MYC expression in MYC-dependent carcinomas.